Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Affiliations

• ¹ Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: [email protected].
• ² Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK.
• ³ Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine.
• ⁴ Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia.
• ⁵ Central Clinical Hospital With Outpatient Clinic, Moscow, Russia.
• ⁶ The Christie NHS Foundation Trust, Manchester, UK.
• ⁷ P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia.
• ⁸ CHU of Québec and Laval University, Québec, QC, Canada.
• ⁹ Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
• ¹⁰ Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
• ¹¹ Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
• ¹² Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland.
• ¹³ Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine.
• ¹⁴ Taipei Veterans General Hospital, Taipei, Taiwan.
• ¹⁵ Bell Land General Hospital, Osaka, Japan.
• ¹⁶ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
• ¹⁷ Merck & Co., Inc., Rahway, NJ, USA.
• ¹⁸ MSD UK, London, UK.
• ¹⁹ University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
• ²⁰ Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.